ArticleAsian Pacific journal of cancer prevention : APJCP2026
Cytogenetic Profile of Newly Diagnosed Acute Myeloid Leukemia Patients: Insights from a Study at a Tertiary Care Centre in South India.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute Myeloid Leukemia (AML) is a heterogeneous hematologic malignancy characterized by a wide range of cytogenetic abnormalities that have critical diagnostic and prognostic implications. South Indian populations are underrepresented in global AML research, warranting region-specific cytogenetic profiling.
methodsWe performed a cytogenetic analysis of 400 newly diagnosed adult AML patients at a tertiary care center in South India. Conventional karyotyping and fluorescence in situ hybridization (FISH) were performed, and findings were correlated with clinical parameters according to the 2016 WHO and FAB classifications.
resultsAbnormal karyotypes were observed in 49.5% of cases, while 50.5% showed normal karyotypes. The most frequent abnormalities were t(15;17) (16.2%), t(8;21) (6.7%), and inv(16) (3.7%). Other notable findings included trisomy 8 (1.7%), trisomy 21 (1%), and complex karyotypes (6.5%). AML-M4 (33.5%) was the most common FAB subtype. Significant associations were noted between cytogenetic risk groups and variables such as age, gender, and white blood cell count. The distribution of cytogenetic aberrations revealed both similarities and distinct differences when compared with global data, reflecting ethnic and geographical influences.
conclusionThis study highlights the cytogenetic diversity of AML in a South Indian cohort and confirms the importance of cytogenetic analysis in disease classification, risk stratification, and therapeutic decision-making. The findings underscore the need for regional data to refine AML diagnosis and optimize management strategies across different populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.